Latest Latent autoimmune diabetes Stories
A recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM) found that the greater an individual's total muscle mass, the lower the person's risk of having insulin resistance, the major precursor of type 2 diabetes.
HIGH WYCOMBE, England, July 21, 2011 /PRNewswire/ -- Using the waterproof* Animas(R) Vibe(TM) Insulin Pump and CGM System, People with Diabetes to Participate in Channel Swim Relay Six swimmers congregate along the Dover coastline today, to participate in a 17-hour relay swim across the English Channel to France.
JDRF says Pending Artificial Pancreas Guidance is FDA's Opportunity to Turn the Tide NEW YORK, July 20, 2011 /PRNewswire-USNewswire/ -- The Juvenile Diabetes Research Foundation (JDRF) welcomed Congress's attention today to the important issue of medical device regulatory reform and reiterated the life-changing difference the FDA's pending artificial pancreas guidance will make in the lives of millions of individuals with type 1 diabetes across the country.
TAMPA, Fla., July 14, 2011 /PRNewswire-USNewswire/ -- In an effort to raise awareness of the effects of excess weight on overall health, the OAC has released a new series of educational brochures. Millions of Americans are affected by excess weight, obesity and severe obesity.
WORCESTER, Mass. and TORONTO, July 8, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTC Bulletin Board: GNBT) (www.generex.com) today announced preliminary clinical results of two major trials using the Generex Oral-lyn(TM) formulation that will be used for registration and marketing.
ORLANDO, Fla., July 7, 2011 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, and the advocacy organization Children with Diabetes, Inc.
ROCKVILLE, Md., June 28, 2011 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, announced the publication in The Lancet of results from Protege, a Phase 3 clinical study of teplizumab in type 1 diabetes.
A major international study collating and analyzing worldwide data on diabetes since 1980 has found that the number of adults with the disease reached 347 million in 2008, more than double the number in 1980.
ROCKVILLE, Md., June 27, 2011 /PRNewswire-USNewswire/ -- Results of two studies testing drugs to slow or stop the immune system's attack on insulin-producing cells in people newly diagnosed with type 1 diabetes will be presented at the American Diabetes Association's (ADA) 71st Scientific Sessions in San Diego and simultaneously published online in the Lancet.
The life expectancy of people diagnosed with type 1 diabetes dramatically increased during the course of a 30-year, long-term prospective study.
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.